FHIR IG analytics
| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113883.3.1444.5.238.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.1444.5.238/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238 |
| Version | 20220112 |
| Status | active |
| Date | 2022-01-12T01:02:12-05:00 |
| Name | FirstLineDrugTherapyForMetastaticColorectalCancer |
| Title | First Line Drug Therapy for Metastatic Colorectal Cancer |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: The purpose of this value set is to represent concepts of medications for first-line drug therapy for metastatic colorectal cancer.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for first-line drug therapy for metastatic colorectal cancer: leucovorin, panitumumab, bevacizumab, capecitabine, cetuximab, pembrolizumab, fluorouracil, oxaliplatin, irinotecan, ipilimumab, nivolumab.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.) |
Resources that use this resource
No resources found
Resources that this resource uses
Narrative
No narrative content found in resource
Source1
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113883.3.1444.5.238",
"meta": {
"versionId": "9",
"lastUpdated": "2023-12-21T17:43:03.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "American Society of Clinical Oncology Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2024-07-31"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2022-01-12"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.3.1444.5.238"
}
],
"version": "20220112",
"name": "FirstLineDrugTherapyForMetastaticColorectalCancer",
"title": "First Line Drug Therapy for Metastatic Colorectal Cancer",
"status": "active",
"experimental": false,
"date": "2022-01-12T01:02:12-05:00",
"publisher": "American Society of Clinical Oncology Steward",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medications for first-line drug therapy for metastatic colorectal cancer.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for first-line drug therapy for metastatic colorectal cancer: leucovorin, panitumumab, bevacizumab, capecitabine, cetuximab, pembrolizumab, fluorouracil, oxaliplatin, irinotecan, ipilimumab, nivolumab.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
"compose": {
"include": [
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.100"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.132"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.210"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.169"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.61"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.63"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.179"
]
},
{
"valueSet": [
"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189"
]
}
]
},
"expansion": {
"identifier": "urn:uuid:0d85d1ed-df10-421b-be9e-bc3911b9a44e",
"timestamp": "2025-05-23T21:57:23-04:00",
"total": 48,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657005",
"display": "40 ML ipilimumab 5 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657012",
"display": "10 ML ipilimumab 5 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657066",
"display": "4 ML bevacizumab 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657073",
"display": "16 ML bevacizumab 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657190",
"display": "4 ML nivolumab 10 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657195",
"display": "10 ML nivolumab 10 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657658",
"display": "50 ML cetuximab 2 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657663",
"display": "100 ML cetuximab 2 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657703",
"display": "5 ML panitumumab 20 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657722",
"display": "20 ML panitumumab 20 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657746",
"display": "pembrolizumab 50 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657750",
"display": "4 ML pembrolizumab 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1719772",
"display": "10 ML irinotecan hydrochloride liposome 4.3 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1726319",
"display": "2 ML irinotecan hydrochloride 20 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1726324",
"display": "5 ML irinotecan hydrochloride 20 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1726333",
"display": "15 ML irinotecan hydrochloride 20 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1726492",
"display": "25 ML irinotecan hydrochloride 20 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1736776",
"display": "10 ML oxaliplatin 5 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1736781",
"display": "20 ML oxaliplatin 5 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1736784",
"display": "oxaliplatin 50 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1736786",
"display": "oxaliplatin 100 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1791701",
"display": "10 ML fluorouracil 50 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1791736",
"display": "20 ML fluorouracil 50 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1797528",
"display": "40 ML oxaliplatin 5 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1803930",
"display": "leucovorin 50 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1803932",
"display": "leucovorin 100 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1803937",
"display": "leucovorin 200 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "197860",
"display": "leucovorin 10 MG Oral Tablet"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "197861",
"display": "leucovorin 15 MG Oral Tablet"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "197862",
"display": "leucovorin 25 MG Oral Tablet"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "197863",
"display": "leucovorin 5 MG Oral Tablet"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1991412",
"display": "24 ML nivolumab 10 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "200327",
"display": "capecitabine 150 MG Oral Tablet"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "200328",
"display": "capecitabine 500 MG Oral Tablet"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2046140",
"display": "16 ML bevacizumab-awwb 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2046148",
"display": "4 ML bevacizumab-awwb 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2055036",
"display": "leucovorin 500 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2099993",
"display": "10 ML leucovorin 10 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2104714",
"display": "50 ML leucovorin 10 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2268039",
"display": "4 ML bevacizumab-bvzr 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2268047",
"display": "16 ML bevacizumab-bvzr 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "237788",
"display": "leucovorin 350 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "239177",
"display": "fluorouracil 50 MG/ML Injectable Solution"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2569080",
"display": "12 ML nivolumab 10 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2599043",
"display": "4 ML bevacizumab-maly 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2599051",
"display": "16 ML bevacizumab-maly 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2627650",
"display": "4 ML bevacizumab-adcd 25 MG/ML Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "2627658",
"display": "16 ML bevacizumab-adcd 25 MG/ML Injection"
}
]
}
}
FHIR
FHIRsmith